摘要
目的探讨安罗替尼治疗晚期肺癌患者的疗效和安全性。方法回顾性分析枣庄市山亭区人民医院2018年至2019年收治的58例应用安罗替尼治疗晚期肺癌患者资料,其中31例患者将安罗替尼用于三线治疗,27例患者用于更多线治疗,评估安罗替尼的疗效和毒性并采用Kaplan-Meier法进行生存分析。结果58例患者均接受治疗评价,46例患者获得无进展生存期评价。10例患者实现了部分缓解(PR),36例实现了稳定疾病(SD),缓解率和疾病控制率(DCR)分别为17.2%和77.6%,中位无进展生存期(PFS)为3.3个月(95%CI 1.595~5.071)。与安罗替尼有关的毒性一般可以接受,3级以上毒性只有5.2%,最常见的毒性是手足综合征和高血压。结论安罗替尼用于晚期肺癌的三线或更多线治疗,不良反应是可控的,其作为最后挽救性治疗手段具有一定可行性。
Objective To explore the efficacy and safety of arotinib in the treatment of advanced lung cancer.Methods A retrospective analysis was made of 58 patients with advanced lung cancer who were treated with arotinib from 2018 to 2019 in Shanting District People’s Hospital of Zaozhuang City.Among them,31 patients were treated with arotinib for the third line treatment,and 27 patients were treated with more lines.The efficacy and toxicity of arotinib were evaluated and survival analysis was carried out by Kaplan Meier method.Results A total of 58 patients had therapeutic evaluation and 46 patients acquired progression-free survival evaluation.A total of 10 patients achieved partial response(PR),and 36 achieved stable disease(SD).Remission rate and disease control rate(DCR)were 17.2%and 77.6%,respectively.Median progression-free survival was 3.3 months(95%CI 1.595-5.071).The toxicities associated with anlotinib were generally acceptable with grade 3 toxicity above is only 5.2%.The most common toxicities are hand-foot syndrome and hypertension.Conclusion Anlotinib is used in the third-line or more treatment of advanced lung cancer.The adverse reactions are controllable,and it is feasible as a last resort treatment.
作者
杨凤伟
张建鑫
YANG Feng-Wei;ZHANG Jian-Xin(Department of Oncology,Zaozhuang Shanting District People's Hospital,Zaozhuang 277200,China)
出处
《中国药物经济学》
2020年第1期42-46,共5页
China Journal of Pharmaceutical Economics
作者简介
通信作者:张建鑫,E-mail:724967074@qq.com
